Condition of low SYSTEMIC VASCULAR RESISTANCE that develops secondary to other conditions such as ANAPHYLAXIS; SEPSIS; SURGICAL SHOCK; and SEPTIC SHOCK. Vasoplegia that develops during or post surgery (e.g., CARDIOPULMONARY BYPASS) is called postoperative vasoplegic syndrome or vasoplegic syndrome.
Also Known As:
Post operative Vasoplegic Syndrome; Post-operative Vasoplegic Syndromes; Syndrome, Post-operative Vasoplegic; Syndromes, Post-operative Vasoplegic; Vasoplegias; Vasoplegic Syndrome, Post-operative; Vasoplegic Syndromes, Post-operative; Post-operative Vasoplegic Syndrome; Postoperative Vasoplegic Syndrome; Vasoplegic Syndrome
Networked: 128 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Hypotension (Low Blood Pressure)
2. Burns
3. Septic Shock (Toxic Shock Syndrome)
4. Sepsis (Septicemia)
5. Anaphylaxis (Anaphylactic Shock)


1. Fischer, Gregory W: 5 articles (01/2016 - 10/2009)
2. Rodrigues, Alfredo José: 5 articles (01/2015 - 10/2006)
3. Evora, Paulo Roberto Barbosa: 5 articles (01/2015 - 10/2006)
4. Vicente, Walter Vilella de Andrade: 4 articles (01/2015 - 10/2006)
5. Evora, Paulo Roberto B: 4 articles (05/2012 - 03/2004)
6. Gomes, Walter J: 3 articles (06/2010 - 02/2003)
7. Hosseinian, Leila: 2 articles (01/2016 - 12/2013)
8. Levin, Matthew A: 2 articles (01/2016 - 10/2009)
9. Bassetto, Solange: 2 articles (01/2015 - 07/2009)
10. Alves Junior, Lafaiete: 2 articles (01/2015 - 07/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vasoplegia:
1. Methylene Blue (Methylthioninium Chloride)FDA Link
2. Guanylate Cyclase (Guanylyl Cyclase)IBA
05/01/2012 - "In the last 2 decades, studies have reported promising results from the administration of an NO competitor, methylene blue (MB), which is an inhibitor of the soluble guanylate cyclase (sGC), in the treatment of refractory cases of vasoplegia. "
07/01/2009 - "There is strong evidence that methylene blue (MB), an inhibitor of guanylate cyclase, is an excellent therapeutic option for vasoplegic syndrome (VS) treatment in heart surgery. "
06/01/2003 - "Guanylate cyclase inhibitors could be a novel class of agents for the treatment of norepinephrine-refractory vasoplegia after cardiopulmonary bypass. "
05/01/2012 - "Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. "
01/01/2008 - "Thus, some points, to a certain extent philosophical, have motivated this revision: a) To preserve and update the surgeon knowledge regarding CPB, even to keep his/her pedagogical leadership on his/her surgical team; b) To question if elderly and diabetic patients, as a result of their individual characteristics deserve more appropriate protocols similar to those adopted for children; c) One third aspect would be the questioning of the systemic inflammatory reaction caused by the blood exposure to CPB non-endothelized circuit surface, in face of the increasing importance of blood contact with the surgical wound; d) In relation to the treatment of the vasoplegic syndrome, methylene blue continues being the best therapeutical option, even so, many times are not efficient on account of a highly probable existence of a "therapeutical window" based on the guanylate cyclase dynamics of action (saturation and synthesis "de novo") and; finally, e) The reason of the title, highlighting that based on its current patterns, would the CPB be an outcome of empiricism, art, or science? "
3. Vasopressins (Vasopressin)IBA
4. Nitric Oxide Synthase (NO Synthase)IBA
02/01/2014 - "Nitric oxide induced by a Ca(+2) independent isoform of nitric oxide synthase has been suggested to play an important role in sepsis-induced vasoplegia. "
12/01/1996 - "Endotoxin (lipopolysaccharide, LPS)-induced hypotension is, in part, mediated via induction of nitric oxide synthase (iNOS), release of nitric oxide, and suppression of vascular reactivity (vasoplegia). "
05/01/2008 - "In search of effective treatment for vasoplegia, methylene blue (MB), an inhibitor of nitric oxide synthase (NOS) and guanylate cyclase (GC), has been found to improve the refractory hypotension associated with endothelial dysfunction of VS. There is evidence that MB may indeed be effective in improving systemic hemodynamics in the setting of vasoplegia, with reportedly few side effects. "
12/01/2011 - "Methylene blue, an inhibitor of nitric oxide synthase and guanylate cyclase, may contribute to the improvement of refractory hypotension associated with endothelial dysfunction in vasoplegia. "
02/01/2015 - "The aim of this review is to discuss in detail the recent suggested alternative mechanisms of vasoplegia in severe sepsis: Overproduction of nitric oxide (NO) by activation of inducible form of nitric oxide synthase (iNOS); up-regulation of prostacyclin (PG12); vasopressin deficiency; significantly elevated levels of circulating endothelin; increased concentrations of vasodilator peptides such as adrenomedulin (AM) and calcitonin gene-related peptide (CGRP); oxidative stress inducing endothelial dysfunction and vascular hyporeactivity to vasoconstrictors; inactivation of catecholamines by oxidation; over-activation of ATP-sensitive potassium channels (KATP channels) during septic shock and their involvement in vascular dysfunction. "
5. Norepinephrine (Noradrenaline)FDA LinkGeneric
6. Carbon MonoxideIBA
7. Nitric Oxide (Nitrogen Monoxide)FDA Link
09/01/2010 - "Release of nitric oxide in the systemic circulation can be a potential cause of vasoplegic syndrome. "
06/01/1996 - "A role for nitric oxide in the vasoplegic syndrome."
12/01/1996 - "Our data suggest that induction of HSP expression protects rats from LPS by blocking LPS-induced iNOS expression, leading to inhibition of the overproduction of nitric oxide and thereby reversing LPS-induced vasoplegia and LPS-induced hypotension."
10/02/2009 - "Based on these thoughts we attempted to hypothesize the causes of why this proposed discussion is not an inciting issue: (I) First hypothesis: An endothelium dysfunction classification is not important; (II) Second hypothesis: Such classification is still a "premature reductionism"; (III) Third hypothesis: Endothelium dysfunction is a multifaceted disorder and involves uncountable variations becoming impossible to propose an adequate classification; (IV) Fourth hypothesis: Vasoplegic syndrome and massive nitric oxide release accounts for the functional classification, thus, it seems that cardiovascular journals feel apprehensive about this since their point of view is closely associated with impaired endothelium nitric oxide release as a cause to increased risk of spasm and thrombosis and; (V) Fifth hypothesis: The classification is so fulfilling that it discards the need of discussion or the pioneer attitude to propose such classification has incited some degree of jealousy. "
08/01/2012 - "The accentuated nitric oxide (NO) release that is induced by the systemic inflammatory response associated with infective endocarditis (IE) and cardiopulmonary bypass (CPB) may result in catecholamine refractory hypotension (vasoplegia) and increased transfusion requirement due to platelet inhibition. "
8. Peroxynitrous Acid (Peroxynitrite)IBA
9. Epinephrine (Adrenaline)FDA LinkGeneric
10. Vasoconstrictor AgentsIBA

Therapies and Procedures

1. Cardiopulmonary Bypass (Heart-Lung Bypass)
2. Resuscitation
3. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4. Cardiac Surgical Procedures
5. Transplants (Transplant)